The real-world OS estimates for advanced NSCLC observed in Swedish patients receiving first-line PD-(L)1 inhibitor-based therapy were similar to what has been reported in pivotal clinical trials. This evidence concerns the gene CD274 and non-small cell lung carcinoma.